BioStock: Positive phase II results for Curasight in head and neck cancer

In their Q3-report, Danish Curasight signalled an upcoming interesting news flow. Two weeks later, the company started delivering on that promise with positive data coming from one of the investigator-initiated phase II studies with uTRACE, where the PET-tracer showed potential as a future tool in the treatment of head and neck cancer patients. BioStock reached out to Curasight CEO Ulrich Krasilnikoff to learn more.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/12/positive-phase-ii-results-for-curasight-in-head-and-neck-cancer/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se